Federated Hermes
PRLD icon

Federated Hermes’s Prelude Therapeutics PRLD Stock Holding History

Federated Hermes’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65
Closed -$393 – 2228
2022
Q4 		$393 Sell
65
-1,342
-95% -$8.6K ﹤0.01% 2098
2022
Q3 		$9K Buy
1,407
+1,141
+429% +$7.69K ﹤0.01% 1844
2022
Q2 		$1K Buy
+266
New +$1.35K ﹤0.01% 2070
2021
Q4 		– Sell
-408,100
Closed -$12.8M – 2286
2021
Q3 		$12.8M Buy
408,100
+72,000
+21% +$2.33M 0.02% 586
2021
Q2 		$9.62M Hold
336,100
– – 0.02% 674
2021
Q1 		$14.6M Buy
336,100
+186,100
+124% +$12.3M 0.03% 570
2020
Q4 		$10.7M Hold
150,000
– – 0.02% 625
2020
Q3 		$4.52M Buy
+150,000
New +$4.24M 0.01% 754

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's PRLD Position: Q1 2023 in Review

Federated Hermes sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 65 shares — an estimated $393 sold.

Federated Hermes first reported a position in PRLD in Q3 2020 and held it in 8 quarters. The position peaked at $14.6M in Q1 2021. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • Federated Hermes reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 65 Prelude Therapeutics shares in Q1 2023, an estimated $393.
  • Federated Hermes first reported a position in Prelude Therapeutics in Q3 2020 and held it in 8 quarters.
  • Federated Hermes's Prelude Therapeutics position peaked at $14.6M in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.